Keywords: Belgium, Biomedica competitiveness, R&D spending

Belgium must address its loss of competitiveness, including in Biopharma

Article | 13 January 2010

At the end of 2009, the Belgian Central Council of the Economy (the CEC) attracted attention to the country’s loss ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in